Azacitidine

years and older who failed treatment with at least one hypomethylating agent, such as azacitidine or decitabine. ❋ Unknown (2010)

News) ("Cyclacel") announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents, such as azacitidine and decitabine. ❋ Unknown (2010)

The Food and Drug Administration approved azacitidine in May 2004; the drug is now marketed as Vidaza. ❋ Unknown (2009)

In the 1980s, as a young oncology fellow at Mount Sinai School of Medicine in New York, Lewis Silverman proposed testing azacitidine as an epigenetic drug — that is, at lower doses than is typical for traditional chemotherapy, where it still might be effective reversing silenced genes. ❋ Unknown (2009)

Last year, the Food and Drug Administration approved the first epigenetic drug, azacitidine , which treats a form of leukemia by reactivating those genes. ❋ Unknown (2005)

One of the drugs used in the study, azacitidine, had been tested on different cancers decades ago but was deemed too toxic to use. ❋ Unknown (2011)

These researchers also used low doses of azacitidine, combined with a newer drug, etinostat. ❋ Unknown (2011)

MONDAY, March 29 (HealthDay News) -- The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study. ❋ Unknown (2010)

The first patient was treated in a phase II investigator-sponsored trial of lintuzumab in combination with Vidaza (azacitidine) for patients with myelodysplastic syndromes ❋ Unknown (2010)